Coherus Biosciences | CHRS - Ordinary Share Capital


Coherus Biosciences reported $121.16M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Acadia Pharmaceuticals USD 171.09M 1.9M Mar/2026
Akebia Therapeutics USD 265.42M 199K Dec/2025
ALKERMES USD 167.54M 1.08M Jun/2026
Alnylam Pharmaceuticals USD 133.73M 290K Jun/2026
Amarin USD 20.81M 13K Dec/2025
Amgen USD 541M 1000K Jun/2026
Baxter International USD 517M 549K Jun/2026
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.54M 267K Jun/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Coherus Biosciences USD 121.16M 4.92M Dec/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Fujifilm JPY 1.21B 33K Mar/2026
Gilead Sciences USD 1.24B 1000K Jun/2026
Ironwood Pharmaceuticals USD 160K 0 Dec/2024
Merck USD 2.47B 4.93M Mar/2026
Myriad Genetics USD 93.5M 400K Dec/2025
Pacira USD 39.82M 512K Jun/2026
Perrigo USD 138.1M 500K Mar/2026
Pfizer USD 5.7B 0 Jun/2026
PTC Therapeutics USD 82.88M 1.41M Mar/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Sarepta Therapeutics USD 105.62M 53K Jun/2026
Teva Pharmaceutical Industries USD 1.16B 1000K Jun/2026
Vertex Pharmaceuticals USD 253.3M 900K Jun/2026
Xencor USD 74.33M 265K Jun/2026
Zoetis USD 414.15M 6.19M Jun/2026